Navigation Links
Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
Date:3/31/2008

p>well as other specified compounds.

Renamed Company to reflect strategic vision.

In June 2007, Boston Life Sciences was renamed Alseres Pharmaceuticals.

The new name, which derives from the Latin meaning to take root and grow,

better reflects the transformation of the Company from a life sciences

company into a biopharmaceutical company with late stage product

candidates in clinical development for CNS disorders.

Raised $27 million in new cash in 2007, an additional $5 million in

2008 and eliminated $10 million of debt.

-- In early 2007, we borrowed $2 million in debt that, along with the $8

million of debt outstanding at December 31, 2006, converted into our

common stock in June 2007.

-- In 2007 and in March 2008, we borrowed an aggregate of $30 million

under convertible notes that mature on December 31, 2010. These notes

are convertible into our common stock at a conversion price of $2.50

per share or the right to receive future payments related to our

molecular imaging products (including ALTROPANE and FLUORATEC) in

amounts equal to 2% of our pre-commercial revenue related to such

products plus 0.5% of future net sales of such products for each

$1,000,000 of outstanding principal and interest that a purchaser under

this agreement elects to convert into future payments.

Organizational Highlights

Continued to expand management team with key additions.

In 2007, Alseres added Dr. Frank Bobe to the position of Executive Vice

President and Chief Business Officer and Susan Flint to the position of

Senior Vice President Drug Development.

Continued development of the Board of Directors.

In 2007, Alseres elected Gary Frasier and Henry Brem to its Board of

Directors. The Company also formed a Science and Technology Committee

comprised of independent director
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call
2. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
3. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
4. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
5. Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the Peoples Republic of China
6. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
7. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
8. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
9. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
10. Investor Alert from Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of CollaGenex Pharmaceuticals, Inc. - CGPI
11. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Cambridge Semantics, the leading provider of ... that 2014 was a record-breaking year across the board for ... Anzo Smart Data Platform and our Smart Data solutions, our ... diverse data which led to record growth for the company ...
(Date:1/22/2015)... 2015 Crystal Diagnostics (CDx) Xpress System, a ... received AOAC-PTM Certifications for the six non-O157 Shiga toxin-producing E. ... referred to as STEC or the “Big-6”) as well as ... (cfu) per 325 g of raw ground beef and raw ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Dr. Greg Leyer ... 12th annual Scripps Natural Supplements Pre-Conference seminar on probiotics in ... is an annual continuing education conference for health care professionals. ... included the topic of probiotics in health. Dr. Leyer spoke ...
(Date:1/22/2015)... Denville, NJ (PRWEB) January 22, 2015 ... shearing technologies such as the Bioruptor® and complete ... semi-automation system for chromatin immunoprecipitation, alleviating the need ... reagents and controls needed for ChIP of histones ...
Breaking Biology Technology:Cambridge Semantics Announces Record Results for 2014 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2
... Systems Inc. (Other,OTC: BMXSF), is pleased to announce ... Ltd., for the provision of the design, manufacture,and ... engagement,letter, Alcofuel Technologies has agreed, subject to the ... and manufacture a small,scale ethanol micro-refinery capable of ...
... 16 ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ... on commercializing proprietary product candidates for the ... that the U.S. Food and,Drug Administration (FDA) ... CoFactor(R) injection, which is currently being investigated ...
... Application in the Fourth ... Quarter, ... results from a 12-week, Phase 3 clinical,trial of FENTORA(R) (fentanyl buccal tablet) ... non-cancer pain,conditions. The study achieved statistical significance on the primary,endpoint. Results across ...
Cached Biology Technology:BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery 2ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer 2ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer 3Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 2Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 3Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 4Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 5
(Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ...
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ...
(Date:12/11/2014)... 09, 2014 Research and Markets , ... ) has announced the addition of the "Biometrics ... offering. One major trend emerging in ... in technology, it is important to upgrade biometric solutions ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... Calgary researchers, published today in PLoS ONE, demonstrates the ... human activity. The research was conducted by ... Post-Doctoral Fellow and two University of Calgary professors from ... the Schulich School of Engineering and the Faculty of ...
... of the Division of Sleep Medicine at Brigham and Women,s ... Space Biomedical Research Institute (NSBRI) for a postdoctoral fellowship. ... the United States has to offer. These new fellows will ... health and to improve health care on Earth," said Dr. ...
... our landscape consuming insects, but they do this in secret, ... unable to bring their ecosystem out of the dark but ... Bristol and Biodiversity Institute of Ontario, Canada, have been able ... Working at three sites in Southern Ontario (Canada) the team ...
Cached Biology News:Humans give prey the edge in food web 2Brigham and Women's Hospital researcher named National Space Biomedical Research Institute Fellow 2Food forensics: DNA links habitat quality to bat diet 2
Reported to support murine B lymphocytes, hematopoietic tissue from bone marrow, B cells stimulated with lipopolysaccharide, T lymphocytes, and a variety of hybrid cells....
... F-12 was developed for culturing hybrid cells ... modification consists of doubling the amino acids ... salt concentrations have been altered as well. ... per liter, which may render it unsuitable ...
... Alsevers solution is an isotonic, balanced salt ... preservative, which permits the storage of whole blood ... usage, an equal volume of blood is collected ... but thoroughly, mixed. The solution is placed in ...
... or individual RNA sequences from high throughput synthesis ... RNAs from LC Sciences. These products provide a ... of DESIGNED sequences delivered in a microtube as ... a single verified RNA sequence. This is a ...
Biology Products: